API SUPPLIERS

API Suppliers

0

US DMFs Filed

0

CEP/COS Certifications

0

JDMFs Filed

0

EU WC

0

Listed Suppliers

0

API REF. PRICE (USD / KG)

0

API Market Place

0

INTERMEDIATES

0

DOSSIERS // FDF

USA (Orange Book)

0

Europe

0

Canada

0

Australia

0

South Africa

0

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

FDF Market Place

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

0

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Full Screen View

Merck & Co

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Merck Initiates Phase 3 Clinical Program for Oral PCSK9 Inhibitor Candidate MK-0616

Details:

MK-0616 is an investigational macrocyclic peptide that binds to PCSK9 and inhibits the interaction of PCSK9 with LDL receptors resulting in greater numbers of LDL receptors available on the cell surface to remove LDL cholesterol from the blood.

Lead Product(s): MK-0616

Therapeutic Area: Cardiology/Vascular Diseases Product Name: MK-0616

Highest Development Status: Phase IIIProduct Type: Peptide

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 25, 2023

ASK
US

Upload
your Marketing & Sales content

Merck & Co

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Merck’s MK-0616, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Patients with Hypercholesterolemia in Phase 2b Study

Details:

MK-0616 is an investigational macrocyclic peptide that binds to PCSK9 and inhibits the interaction of PCSK9 with LDL receptors resulting in greater numbers of LDL receptors available on the cell surface to remove LDL cholesterol from the blood.

Lead Product(s): MK-0616

Therapeutic Area: Cardiology/Vascular Diseases Product Name: MK-0616

Highest Development Status: Phase IIProduct Type: Peptide

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 06, 2023

ASK
US

Upload
your Marketing & Sales content

Merck Group

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Merck to Present New Data for Sotatercept and MK-0616 at ACC.23/WCC, Demonstrating Significant Progress in Advancing Its Innovative Cardiovascular Pipel...

Details:

MK-0616 is an investigational macrocyclic peptide that binds to PCSK9 and inhibits the interaction of PCSK9 with LDL receptors resulting in greater numbers of LDL receptors available on the cell surface to remove LDL cholesterol from the blood.

Lead Product(s): MK-0616

Therapeutic Area: Cardiology/Vascular Diseases Product Name: MK-0616

Highest Development Status: Phase IIProduct Type: Peptide

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 21, 2023

ASK
US

Upload
your Marketing & Sales content